IP Library Patent Application 10520333
Patent Application
App. No. 10/520,333

Vaccine for feline infectious peritonitis

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/520,333
Abstract

FIP vaccines were provided that use an N protein with a specific structure, or a fragment thereof, as an antigen. Preferred antigens of this invention are N proteins derived from a specific type I virus strain (KU-2). Vaccines comprising such an N protein confer preventive effects against a wide range of FIPVs. In addition, the N proteins are very safe because they do not comprise epitopes that enhance infection. Furthermore, preventive effects can be accomplished against type I viruses, which actually cause 70% or more of FIP.

Claims (39)

1 . A vaccine for treating and/or preventing feline infectious peritonitis, wherein said vaccine comprises a protein comprising an amino acid sequence encoded by a polynucleotide of any one of a) to e) as the active ingredient:

a) a polynucleotide comprising a coding region of the nucleotide sequence of SEQ ID NO: 1;

b) a polynucleotide comprising a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO: 2;

c) a polynucleotide comprising a nucleotide sequence with 93% or more homology to a nucleotide sequence of a coding region of the nucleotide sequence of SEQ ID NO: 1;

d) a polynucleotide comprising a nucleotide sequence with 93% or more homology to the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 2; and

e) a polynucleotide encoding a continuous amino acid sequence comprising 45 or more amino acid residues, selected from an amino acid sequence encoded by the polynucleotide of any one of a) to d).

2 . A vaccine for treating and/or preventing feline infectious peritonitis, wherein said vaccine comprises a polynucleotide of any one of a) to e) as the active ingredient:

a) a polynucleotide comprising a coding region of the nucleotide sequence of SEQ ID NO: 1;

b) a polynucleotide comprising a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO: 2;

c) a polynucleotide comprising a nucleotide sequence with 93% or more homology to a nucleotide sequence of a coding region of the nucleotide sequence of SEQ ID NO: 1;

d) a polynucleotide comprising a nucleotide sequence with 93% or more homology to the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 2; and

e) a polynucleotide encoding a continuous amino acid sequence comprising 45 or more amino acid residues, selected from an amino acid sequence encoded by the polynucleotide of any one of a) to d).

3 . The vaccine of claim 1 , wherein the polynucleotide is the polynucleotide of a) or b).

4 . An antibody formulation for treating and/or preventing feline infectious peritonitis, wherein said formulation comprises, as an active ingredient, an antibody that can bind to a protein comprising an amino acid sequence encoded by a polynucleotide of any one of a) to e):

a) a polynucleotide comprising a coding region of the nucleotide sequence of SEQ ID NO: 1;

b) a polynucleotide comprising a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO: 2;

c) a polynucleotide comprising a nucleotide sequence with 93% or more homology to a nucleotide sequence of a coding region of the nucleotide sequence of SEQ ID NO: 1;

d) a polynucleotide comprising a nucleotide sequence with 93% or more homology to the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 2; and

e) a polynucleotide encoding a continuous amino acid sequence comprising 45 or more amino acid residues, selected from an amino acid sequence encoded by the polynucleotide of any one of a) to d).

5 . A method for treating and/or preventing feline infectious peritonitis, wherein said method comprises the process of administering the vaccine of claim 1 to a cat at least once.

6 . A method for treating and/or preventing feline infectious peritonitis, wherein said method comprises the process of administering the antibody formulation of claim 4 to a cat at least once.

7 . A method of testing for feline infectious peritonitis virus infection, wherein said method comprises the steps of:

incubating cat serum with a protein comprising an amino acid sequence encoded by a polynucleotide of any one of a) to e):

a) a polynucleotide comprising a coding region of the nucleotide sequence of SEQ ID NO: 1;

b) a polynucleotide comprising a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO: 2;

c) a polynucleotide comprising a nucleotide sequence with 93% or more homology to a nucleotide sequence of a coding region of the nucleotide sequence of SEQ ID NO: 1;

d) a polynucleotide comprising a nucleotide sequence with 93% or more homology to the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 2; and

e) a polynucleotide encoding a continuous amino acid sequence comprising 45 or more amino acid residues, selected from an amino acid sequence encoded by the polynucleotide of any one of a) to d); and

detecting an antibody that binds to the protein.

8 . A feline infectious peritonitis viral infection test reagent, comprising a protein that comprises an amino acid sequence encoded by a polynucleotide of any one of a) to e):

a) a polynucleotide comprising a coding region of the nucleotide sequence of SEQ ID NO: 1;

b) a polynucleotide comprising a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO: 2;

c) a polynucleotide comprising a nucleotide sequence with 93% or more homology to a nucleotide sequence of a coding region of the nucleotide sequence of SEQ ID NO: 1;

d) a polynucleotide comprising a nucleotide sequence with 93% or more homology to the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 2; and

e) a polynucleotide encoding a continuous amino acid sequence comprising 45 or more amino acid residues, selected from an amino acid sequence encoded by the polynucleotide of any one of a) to d).

9 . The vaccine of claim 2 , wherein the polynucleotide is the polynucleotide of a) or b).

10 . A method for treating and/or preventing feline infectious peritonitis, wherein said method comprises the process of administering the vaccine of claim 2 to a cat at least once.

11 . A method for treating and/or preventing feline infectious peritonitis, wherein said method comprises the process of administering the vaccine of claim 3 to a cat at least once.

12 . A method for treating and/or preventing feline infectious peritonitis, wherein said method comprises the process of administering the vaccine of claim 9 to a cat at least once.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2012
From: THE KITASATO INSTITUTE
To: KITASATO DAIICHI SANKYO VACCINE CO., LTD.
Reel/Frame 028036/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE POSTAL CODE OF ASSIGNEE/RECEIVING PARTY TO 108-8641 AS PREVIOUSLY RECORDED ON REEL 021965 FRAME 0487. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT POSTAL CODE OF ASSIGNEE/RECEIVING PARTY IS 108-8641. Recorded Jan 23, 2009
From: THE KITASATO INSTITUTE
To: THE KITASATO INSTITUTE
Reel/Frame 022137/0996 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2008
From: THE KITASATO INSTITUTE
To: THE KITASATO INSTITUTE
Reel/Frame 021965/0487 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2005
From: MOTOKAWA, KENJI; KUSUHARA, HAJIME; KOYAMA, HIROYUKI; HOHDATSU, TSUTOMU; ARAI, SETSUO
To: THE KITASATO INSTITUTE
Reel/Frame 016614/0011 →